Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$29.44 0.55 (1.90%)
2/9/2010 4:00 PM

Dendreon Corp (DNDN)

CAPS Rating:
**

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating DNDN

Add Stock to Watchlist

What the Community Thinks

Total Members

1134 Outperforms
297 Underperforms
 

All-Stars

354 Outperforms
80 Underperforms
 

Wall Street

14 Outperforms
3 Underperforms
 

Members bullish on DNDN are also bullish on:

Members bearish on DNDN are also bearish on:

Ticker Tags

Biotechnology (220), Growth (1902), Mid Cap (610), Aggressive Growth (860), Healthcare (711), Defensive (1457), Rule Breakers Universe (125)
Suggest a tag

Dendreon Corp At A Glance

Current Price: $29.44
Last Trade Time: 2/9/2010 4:00 PM
Open: $29.22
Previous Close: $28.89
Daily Range: $28.95 - $29.51
52-Week Range: $2.55 - $30.90
Volume: 1,529,770
Market Cap: $3.41B
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

DNDN VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

4

Dendreon Corp (DNDN)

Avatar mullings8454 (< 20) Submitted: 10/30/09 11:41 AM

Whole new way of treating cancers, with treatment for breast cancer to follow treatment for prostate cancer. No more chemo or radiation. Amazing technology. Acts like a vaccine. Big companies putting big money into it, i.e. Fidelity Mutual Corp.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

12

Dendreon Corp (DNDN)

Avatar JGus (29.86) Submitted: 5/13/09 8:38 PM

Bet the wrong way on this one. Here's a good lesson for all of you...when it comes to small drug companies, most will fail because the drugs they are developing fail and they run out of money. However, those that actually survive long enough to bring a new drug to market have HUGE upside potential. ...More

Replies: 9 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 328 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (DNDN)

Avatar breaker8 (51.69) Submitted: 2/07/10 11:07 AM : Outperform Start Price: $28.80 DNDN Score: 1.54

FDA approval by May 2010. Big pharma partnership for international marketing rights. Plenty of cash on hand. Ripe for a BIG buyout once commercialization gets closer.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DNDN)

Avatar rvdealer (< 20) Submitted: 2/05/10 12:17 PM : Outperform Start Price: $28.76 DNDN Score: 1.18

dndn is a medical breakthrough, not to mention a possible miracle---there is nothing negative about this company or its product---i believe over time, the cost per treatment will drop---thank you, gregg w. parker

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DNDN)

Avatar seabum49r (48.33) Submitted: 1/19/10 1:52 PM : Outperform Start Price: $29.77 DNDN Score: 5.52

I have been waiting for two years to collect on this at under $4.00 a share, would you say anything else but outperform?

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DNDN)

Avatar anling001 (24.90) Submitted: 1/09/10 12:34 PM : Outperform Start Price: $29.77 DNDN Score: 4.82

Prostate cancer drug pending approval.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (DNDN)

Avatar jonnycolfax (40.11) Submitted: 1/04/10 11:07 AM : Outperform Start Price: $26.90 DNDN Score: 14.69

While many projections for the upper limit of this stock are unreasonably high, FDA approval is highly likely and the sales potential for Provenge is strong. I believe they will see revenue generation in late 2010 and steadily grow over the next several years.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 328 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 17 of 17  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackRothCapital 80.39 01/07/10 Outperform NS $30.00-1.87%-5.53%+3.67
TrackCanaccord 86.15 10/24/09 Outperform NS $28.52+3.23%-2.25%+5.48
TrackLeerinkSwan 92.83 09/22/09 Outperform NS $29.94-1.67%+0.17%-1.84
TrackJimCramer < 20 07/07/09 Outperform 3W $24.02+22.56%+22.34%+0.22
TrackCitigroup 85.92 06/10/09 Outperform NS $26.07+12.93%+13.47%-0.55
TrackDeutscheSec 89.68 06/05/09 Outperform NS $26.75+10.06%+13.42%-3.37
TrackWellsFargo 80.02 04/29/09 Outperform NS $27.00+9.04%+25.24%-16.21
TrackNeedham 67.64 04/29/09 Outperform NS $27.00+9.04%+25.24%-16.21
TrackBreanMurray 86.47 04/29/09 Outperform NS $27.00+9.04%+25.24%-16.21
TrackMerriman < 20 04/22/09 Outperform NS $20.57+43.12%+28.53%+14.59
TrackLazardCapit < 20 04/20/09 Outperform NS $18.66+57.77%+26.65%+31.12
TrackRodmanRen < 20 04/14/09 Outperform NS $17.37+69.47%+27.89%+41.58
TrackZacks 62.21 04/14/09 Outperform 3M $16.99+73.28%+28.44%+44.84 Toggle the visibility of 60-Second Pitch and replies
TrackJMP 71.98 07/12/07 Underperform NS $7.88+273.60%-25.93%-299.53
TrackBofASec 94.61 05/10/07 Underperform NS $5.75+412.00%-24.80%-436.80
TrackUBS 87.99 05/08/07 Underperform NS $17.14+71.76%-24.71%-96.47
TrackNextGen 85.60 05/03/07 Outperform NS $18.13+62.38%-24.43%+86.82

Results 1 - 17 of 17  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD02 15ms